Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy

Abstract

Background Interferon-alpha therapy, which is used to treat metastatic malignant melanoma, can cause patients to develop two distinct neurobehavioral symptom complexes: a mood syndrome and a neurovegetative syndrome. Interferon-alpha effects on serotonin metabolism appear to contribute to the mood and anxiety syndrome, while the neurovegetative syndrome appears to be related to interferon-alpha effects on dopamine.

Purpose Our goal is to propose a design for utilizing a sequential, multiple assignment, randomized trial design for patients with malignant melanoma to test the relative efficacy of drugs that target serotonin versus dopamine metabolism during 4 weeks of intravenous, then 8 weeks of subcutaneous, interferon-alpha therapy.

Methods Patients will be offered participation in a double-blinded, randomized, controlled, 14-week trial involving two treatment phases. During the first month of intravenous interferon-alpha therapy, we will test the hypotheses that escitalopram will be more effective in reducing depressed mood, anxiety, and irritability, whereas methylphenidate will be more effective in diminishing interferon-alpha-induced neurovegetative symptoms, such as fatigue and psychomotor slowing. During the next 8 weeks of subcutaneous interferon therapy, participants whose symptoms do not improve significantly will be randomized to the alternate agent alone versus escitalopram and methylphenidate together.

Results We present a prototype for a single-center, sequential, multiple assignment, randomized trial, which seeks to determine the efficacy of sequenced and targeted treatment for the two distinct symptom complexes suffered by patients treated with interferon-alpha.

Limitations Because we cannot completely control for external factors, a relevant question is whether or not ‘short-term’ neuropsychiatric interventions can increase the number of interferon-alpha doses tolerated and improve long-term survival. Conclusions This sequential, multiple assignment, randomized trial proposes a framework for developing optimal treatment strategies; however, additional studies are needed to determine the best strategy for treating or preventing neurobehavioral symptoms induced by the immunotherapy interferon-alpha. Clinical Trials 2009; 6: 480—490. http://ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-(4th edn), American Psychiatric Association, Washington, DC, 1994.

Dickens CM , McGowan L. , Percival C. , et al. Contribution of depression and anxiety to impaired health-related quality of life following first myocardial infarction. Br J Psychiatry 2006; 189: 367-72.

Fisch MJ , Loehrer PJ , Kristeller J. , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncology 2004; 21: 1937-43.

Reiche EM , Nunes SO , Morimoto HK Stress, depression, the immune system, and cancer. Lancet Oncol 2004; 5: 617-25.

Dantzer R. , O’Connor JC , Freund GG , et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.

Raison C. The effects of hepatitis C and its treatment on mental health. Focus 2006; 21: 4-6.

Cleeland CS , Bennett GJ , Dantzer R. , et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97: 2919-25.

Miller AH Cytokines sing the blues: psychoneuroimmunology at the translational interface . Norman Cousins Lecture. 2008.

Musselman DL , Lawson DH , Gumnick JF , et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-66.

10.

Anderson IM Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.

11.

Song F. , Freemantle N. , Sheldon TA , et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7.

12.

Lavori PW , Dawson R. A design for testing clinical strategies: biased adaptive within-subject randomization . J R Stat Soc 2000; 163: 29-38.

13.

Lavori PW Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials. J Clin Psychopharm 2005; 25: S38-44.

14.

Lavori PW Dynamic treatment regimes: practical design considerations. Clin Trials 2004; 1: 9-20.

15.

Insel TR Beyond efficacy: the STAR*D trial. Am J Psychiatry 2006; 163(1): 5-7.

16.

Miller AH , Ancoli-Israel S. , Bower JE , et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008 ; 26: 971-82.

17.

Hamilton M. The assessment of anxiety states by rating . Br J Med Psychol 1959; 32: 59-65.

18.

Zung WW A self-rating depression scale. Arch Gen Psychiatry 965; 12: 63-70.

19.

Valentine AD , Meyers CA , Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13: 561-66.

20.

First MB , Spitzer RL , Gibbon M. , Williams JBW Structured Clinical Interview for DSM-IV Axis I Disorders, Version 2.0, 9/98 revision. Biometrics Research Department, New York State Psychiatric Institute, New York, 1998.

21.

Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Dept of Health, Education, and Welfare, National Institute of Mental Health ; 1976: 217-222.

22.

Association AP Practice guideline for major depressive disorder in adults. Am J Psychiatry 2005; 162.

23.

Musselman DL , Somerset WI , Guo Y. , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 2006; 67: 288-96.

24.

Nierenberg AA , Katz J. , Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007; 30: 13-29.

25.

Pan W. Akaike’s information criterion in generalized estimating equations . Biometrics 2001; 57: 120-5.

26.

Robins JM , Rotznitsky A. , Zhao LP Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994; 89: 846-66.

27.

Robins JM , Rotznitsky A. , Zhao LP Analysis of the semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc 1995; 90: 106-21.

28.

Murphy SA An experimental design for the development of adaptive treatment strategies . Stat Med 2005; 24: 1455-81.

29.

Murphy SA , Van Der Laan MJ , Robins JM , Group CPR Marginal Mean Models for Dynamic Regimes. J Am Stat Assoc 2001; 96: 1410-23.

30.

Cannistra SA Phase II trials in journal of clinical oncology . J Clin Oncol 2009; 27: 3073-6.

31.

Oetting AI , Levy JA , Weiss RD , Murphy SA Statistical methodology for a SMART design in the development of adaptive treatment strategies 2007. Retrieved from Clinical Trials Network Dissemination Library: http://ctndisseminationlibrary.org/display/187.htm (accessed 17 March 2008).

32.

Dunn AJ , Wang J. , Ando T. Effects of cytokines on cerebral neurotransmission: Comparison with the effects of stress. Adv Exp Med Biol 1999 ; 461: 117-27.

33.

Capuron L. , Miller AH Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819-24.

34.

Spina E. , Scordo MG , D’ Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17: 517-38.

35.

Hirschfeld RM , Vornik LA Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004; 65: 46-52.

36.

Drug therapy for the management of cancer related fatigue (database on the Internet) 2008.

37.

Fleishman S. , Lower E. , Zeldis J. , et al. A phase II, randomized, placebo-controlled trial of the safety and efficacy of dexmethylphenidate (d-MPH) as a treatment for fatigue and ‘chemobrain’ in adult cancer patients. Breast Can Res Treatment 2005; 94: S214.

38.

Rozans M. , Dreisbach A. , Lertora JJ , Kahn MJ Palliative uses of methylphenidate in patients with cancer: a review . J Clin Oncol 2002; 20: 335-39.

39.

Patkar AA , Masand PS , Pae CU , et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26: 653-56.

40.

Rodin G. , Lloyd N. , Katz M. , et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer 2007; 15: 123-36.

41.

Stoll AL , Pillay SS , Diamond L. , et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996; 57: 72-76.

42.

Murphy SA , Lynch KG , Oslin D. , et al. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend 2007; 88: S24-30.

43.

Murphy SA Optimal dynamic treatment regimes. J Royal Stat Soc, Series B 2003; 65: 331-66.

44.

Robins JM, (ed). Optimal structural nested models for optimal sequential decisions. In: Second Seattle Symposium on Biostatistics, Springer, New York, 2004.

45.

Sutton RS , Barto AG Reinforcement learning: an introduction. IEEE Trans Neural Netw 1998; 9: 1054.

46.

Chakraborty B. , Murphy SA Inference for nonregular parameters in optimal dynamic treatment regimes. Stat Methods Med Res 2009 (Epub ahead of print).

47.

Moodie EEM , Richardson TS Estimating optimal dynamic regimes: correcting bias under the null. Scand J Stat 2009 (in press).